Please login to the form below
sacubitril
This page shows the latest sacubitril news and features for those working in and with pharma, biotech and healthcare.
Novartis sues US government over Medicare drug price negotiation programme
The list includes Novartis’ top-selling heart-failure medicine Entresto (sacubitril/valsartan), which the company says is the only angiotensin receptor-neprilysin inhibitor currently approved by the US Food and Drug
Latest news
-
US government announces first ten drugs subject to Medicare pricing negotiations
The list includes Bristol Myers Squibb and Pfizer’s Eliquis (apixaban), Novartis' Entresto (valsartan/sacubitril), Amgen's Enbrel (etanercept), AstraZeneca's Farxiga (dapagliflozin), Merck &Co's Januvia (sitagliptin), Eli Lilly and
-
Novartis sales top £13bn in Q3 as the company reviews its generic business Sandoz
The increase was driven by the strong performance of its heart failure combination Entresto (sacubitril/valsartan) which was up by 44%, psoriasis antibody Cosentyx (secukinumab) up by 22%, myelofibrosis drug Jakavi
-
Novartis sees demand returning to pre-COVID-19 levels in Q2 results
growth of heart failure drug Entresto (sacubitril and valsartan), monoclonal antibody Cosentyx (secukinumab), gene therapy Zolgensma (onasemnogene abeparvovec), wet AMD therapy Lucentis (ranibizumab) and multiple sclerosis drug Kesimpta (ofatumumab).
-
Novartis hit by ‘COVID-19-related lockdowns’ in Q4
added. In the Q4 results, Novartis highlighted its main growth drivers – including its heart failure drug Entresto (sacubitril/valsartan), its immunology therapy Cosentyx (secukinumab) and its spinal muscular atrophy (SMA) gene
-
Novartis weathers the COVID-19 storm in Q3, lifts outlook
sacubitril/valsartan), which grew by 79% and 45% in the quarter, respectively.
More from news
Approximately 6 fully matching, plus 62 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
Entresto (valsartan/sacubitril).
-
Heart failure therapy embarks on a new era
combines the long-established ARB valsartan with sacubitril - a first-in-class neprilysin inhibitor.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Actinic keratosis – a common skin condition that can lead to skin cancer
- The paper trail
- Medscape Education’s Large Presence at IDWeek 2023
- WHO recommends second malaria vaccine for children
- Sanofi enters agreement with Janssen to develop E. coli vaccine candidate
- NFID and CDC urge US adults to get vaccinated against flu and COVID-19
No results were found
PMHub
SEVEN STONES COLLECTIVE
Hello. We are the Total Health creative agency. It’s our collective mix of talent that gets us to truly different...
Latest intelligence
- Actinic keratosis – a common skin condition that can lead to skin cancer
- PMGroup talks to Volker Koscielny, Chief Medical Officer at Almirall, about the importance of remaining vigilant about skin checks, the prevalence of actinic keratosis in the UK and the steps...
- Man vs microbe: the fight against antimicrobial resistance
- How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics...
- Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital
- Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...
